Peer Schroder - Basilea Pharmaceutica Head Relations
| BPMUF Stock | USD 44.45 0.00 0.00% |
Insider
Peer Schroder is Head Relations of Basilea Pharmaceutica AG
| Phone | 41 61 606 11 11 |
| Web | https://www.basilea.com |
Basilea Pharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Basilea Pharmaceutica's management efficiency ratios could be used to measure how well Basilea Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Antony Blanc | CureVac NV | 54 | |
| Ozlem MD | BioNTech SE | 57 | |
| Thorsten Schuller | CureVac NV | N/A | |
| Barbara Wood | Sellas Life Sciences | 61 | |
| Sandra Kolk | ProQR Therapeutics BV | N/A | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| Eyal MBA | Protalix Biotherapeutics | 48 | |
| Craig Mello | Crispr Therapeutics AG | N/A | |
| Lawrence Klein | Crispr Therapeutics AG | 42 | |
| Bartholomew Canton | Ginkgo Bioworks Holdings | N/A | |
| Thomas Knight | Ginkgo Bioworks Holdings | N/A | |
| George Elston | Eyepoint Pharmaceuticals | 59 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Samantha Sutton | Ginkgo Bioworks Holdings | N/A | |
| Ryan Richardson | BioNTech SE | 45 | |
| Melissa Moore | Moderna | N/A | |
| Alfred Boyle | Alnylam Pharmaceuticals | N/A | |
| Stephen Lake | Wave Life Sciences | N/A | |
| Michael Boehler | BioNTech SE | N/A | |
| Mitchell Brigell | Ocuphire Pharma | N/A | |
Management Performance
| Return On Asset | 0.0261 |
Basilea Pharmaceutica Leadership Team
Elected by the shareholders, the Basilea Pharmaceutica's board of directors comprises two types of representatives: Basilea Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Basilea. The board's role is to monitor Basilea Pharmaceutica's management team and ensure that shareholders' interests are well served. Basilea Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Basilea Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lutz Wevelsiep, Head Affairs | ||
| Adesh Kaul, Chief Officer | ||
| Damian Heller, Gen Sec | ||
| Gerrit Hauck, Chief Officer | ||
| David Veitch, Chief Commercial Officer, Member of the Management Committee | ||
| Ursula Eberhardt, Head HR | ||
| Marc MD, Chief Officer | ||
| Peer Schroder, Head Relations | ||
| Dietrich Stber, Head Services | ||
| Laurenz Kellenberger, Chief Scientific Officer |
Basilea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Basilea Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Basilea Pharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Basilea Pharmaceutica's short interest history, or implied volatility extrapolated from Basilea Pharmaceutica options trading.
Pair Trading with Basilea Pharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving against Basilea Pink Sheet
| 0.77 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.7 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.66 | VRTX | Vertex Pharmaceuticals | PairCorr |
| 0.55 | CMXHF | CSL Limited | PairCorr |
| 0.53 | CSLLY | CSL | PairCorr |
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Basilea Pharmaceutica AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets |